Noninvasive diagnostic models for chronic hepatitis B liver fibrosis

Qin YANG; Huaie LIU; Jing YOU; Jie DING; Danyang CHEN

doi:10.3969/j.issn.1001-5256.2021.10.034

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2420-2424

PDF( 2068 KB)

Noninvasive diagnostic models for chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.10.034

1.
Department of Infectious Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
2.
Department of Hepatology, The Third People's Hospital of Kunming, Kunming 650032, China

Research funding:

The High-level Health Technicians-reserve Talents Project of Yunnan Province (H-2017071);

The Scientific Research Project for the Department of Education of Yunnan Province (2021J0239)

Received Date: 2021-02-23
Accepted Date: 2021-03-23
Published Date: 2021-10-20

Abstract

Abstract

Hepatitis B virus (HBV) infection is still a public problem that seriously threatens human health. Evaluation of liver fibrosis progression with an efficient noninvasive model is of great significance for condition assessment, disease management, and prognostic evaluation in patients with chronic HBV infection. This article reviews the noninvasive models commonly used in the diagnosis of liver fibrosis in recent years, summarizes the research background, methods, related studies, and advantages and disadvantages of these models, and analyzes the current research status and possible development trends of liver fibrosis assessment models. Recent studies have shown that although current models are not perfect for Chinese patients with chronic HBV infection as the main predisposing factor for liver fibrosis, the excellent performance of noninvasive models in liver fibrosis assessment provides a reference for the assessment of liver fibrosis in patients with chronic HBV infection and can replace liver biopsy to a certain extent.
- Hepatitis B, Chronic,
- Liver Cirrhosis,
- Diagnostic

FullText(HTML)

References(40)

References

[1]	CORNBERG M, LOK AS, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV treatment endpoints conference[J]. J Hepatol, 2020, 72(3): 539-557. DOI: 10.1016/j.jhep.2019.11.003.
[2]	European Association for the Study of the liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[3]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[4]	BOYD A, CAIN O, CHAUHAN A, et al. Medical liver biopsy: Background, indications, procedure and histopathology[J]. Frontline Gastroenterol, 2020, 11(1): 40-47. DOI: 10.1136/flgastro-2018-101139.
[5]	AHMAD W, LJAZ B, JAVED FT, et al. A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI)[J]. BMC Gastroenterol, 2011, 11: 44. DOI: 10.1186/1471-230X-11-44.
[6]	LI Q, LU C, LI W, et al. Globulin-platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels[J]. Clin Exp Med, 2018, 18(1): 71-78. DOI: 10.1007/s10238-017-0472-3.
[7]	LIU XD, WU JL, LIANG J, et al. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients[J]. World J Gastroenterol, 2012, 18(22): 2784-2792. DOI: 10.3748/wjg.v18.i22.2784.
[8]	COSKUN BD, ALTINKAYA E, SEVINC E, et al. The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients[J]. Rev Esp Enferm Dig, 2015, 107(12): 740-744. DOI: 10.17235/reed.2015.3851/2015.
[9]	WANG L, LI J, YANG K, et al. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels[J]. Medicine (Baltimore), 2020, 99(23): e20548. DOI: 10.1097/MD.0000000000020548.
[10]	CHEN B, YE B, ZHANG J, et al. RDW to platelet ratio: A novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B[J]. PLoS One, 2013, 8(7): e68780. DOI: 10.1371/journal.pone.0068780.
[11]	MAO W, WU J. Haematologic indices in hepatitis B virus-related liver disease[J]. Clin Chim Acta, 2020, 500: 135-142. DOI: 10.1016/j.cca.2019.10.007.
[12]	CAI Y, LIU D, CUI J, et al. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting staging liver fibrosis in chronic liver disease patients: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(14): e15096. DOI: 10.1097/MD.0000000000015096.
[13]	YUYUN D, ZHIHUA T, HAIJUN W, et al. Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis[J]. Scand J Gastroenterol, 2019, 54(1): 81-86. DOI: 10.1080/00365521.2018.1558786.
[14]	KANG NL, ZHANG JM, LIN MX, et al. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients[J]. World J Gastroenterol, 2020, 26(27): 3952-3962. DOI: 10.3748/wjg.v26.i27.3952.
[15]	LAI L, SU T, LIANG Z, et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus-associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy[J]. J Cancer, 2020, 11(22): 6642-6652. DOI: 10.7150/jca.47291.
[16]	CHEN C, ZHAI YF, ZHANG HH. Value of aspartate aminotransferase-to-platelet ratio index in judging the indication for antiviral therapy in patients with chronic HBV infection and alanine aminotransferase less than two times of upper limit of normal[J]. J Clin Hepatol, 2018, 34(5): 1005-1010. DOI: 10.3969/j.issn.1001-5256.2018.05.016. 陈晨, 翟玉峰, 张怀宏. APRI对ALT < 2倍正常值上限慢性HBV感染抗病毒治疗指征的判断价值[J]. 临床肝胆病杂志, 2018, 34(5): 1005-1010. DOI: 10.3969/j.issn.1001-5256.2018.05.016.
[17]	DONG XQ, WU Z, ZHAO H, et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in Chinese hepatitis B patients[J]. J Viral Hepat, 2019, 26(2): 297-307. DOI: 10.1111/jvh.13031.
[18]	XU XY, WANG WS, ZHANG QM, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. World J Clin Cases, 2019, 7(15): 2022-2037. DOI: 10.12998/wjcc.v7.i15.2022.
[19]	JIN L, LI X, YE J, et al. The diagnostic value of FIB-4 for liver inflammation and fibrosisin antiviral treatment of HBeAg-negative chronic HBV infected patients[J]. Acta Univ Med Anhui, 2020, 55(6): 960-964. DOI: 10.19405/j.cnki.issn.1000-1492. 金蕾, 李旭, 叶珺, 等. FIB-4对HBeAg阴性慢性HBV感染者抗病毒治疗指征中肝脏炎症和纤维化的判断价值[J]. 安徽医科大学学报, 2020, 55(6): 960-964. DOI: 10.19405/j.cnki.issn.1000-1492.
[20]	WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015[EB/OL]. [2021-02-23]. https://www.who.int/hiv/pub/hepatitis/hepatitisb-guidelines/en/.
[21]	XU HH, GAO YF. Predictive value of King's index in noninvasive diagnosis of liver fibrosis degrees in patients with chronic hepatitis B virus infection[J]. Anhui Med J, 2020, 41(5): 505-509. DOI: 10.3969/j.issn.1000-0399. 徐洪海, 郜玉峰. King指数无创诊断慢性HBV感染患者肝纤维化程度的预测价值[J]. 安徽医学, 2020, 41(5): 505-509. DOI: 10.3969/j.issn.1000-0399.
[22]	ÇELIK D, TATAR B, KÖSE Ș, et al. Evaluation of the diagnostic validity of noninvasive tests for predicting liver fibrosis stage in chronic hepatitis B patients[J]. Acta Gastroenterol Belg, 2020, 83(3): 419-425.
[23]	GUO H, ZHU B, LI S, et al. Development and validation of a novel model to predict liver histopathology in patients with chronic hepatitis B[J]. Biomed Res Int, 2019, 2019: 1621627. DOI: 10.1155/2019/1621627.
[24]	LEMOINE M, SHIMAKAWA Y, NAYAGAM S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut, 2016, 65(8): 1369-1376. DOI: 10.1136/gutjnl-2015-309260.
[25]	LEE J, KIM MY, KANG SH, et al. The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection[J]. Br J Biomed Sci, 2018, 75(3): 128-132. DOI: 10.1080/09674845.2018.1459147.
[26]	TAG-ADEEN M, OMAR MZ, ABD-ELSALAM FM, et al. Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes[J]. Medicine (Baltimore), 2018, 97(6): e9781. DOI: 10.1097/MD.0000000000009781.
[27]	KAYADIBI H, YILMAZ B, OZGUR YENIOVA A, et al. Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection[J]. Eur J Gastroenterol Hepatol, 2020. DOI: 10.1097/MEG.0000000000001973.[Online ahead of print]
[28]	CELIKBILET M, DOGAN S, GURSOY S, et al. Noninvasive assessment of liver damage in chronic hepatitis B[J]. World J Hepatol, 2013, 5(8): 439-445. DOI: 10.4254/wjh.v5.i8.439.
[29]	PREMKUMAR M, SAXENA P, RANGEGOWDA D, et al. Coagulation failure is associated with bleeding events and clinical outcome during systemic inflammatory response and sepsis in acute-on-chronic liver failure: An observational cohort study[J]. Liver Int, 2019, 39(4): 694-704. DOI: 10.1111/liv.14034.
[30]	TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476.
[31]	QIANG L, QIN J, SUN C, et al. A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: A retrospective cohort study[J]. BMC Gastroenterol, 2020, 20(1): 301. DOI: 10.1186/s12876-020-01437-2.
[32]	REN A, LI Z, ZHANG X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation[J]. J Hepatocell Carcinoma, 2020, 7: 101-106. DOI: 10.2147/JHC.S259992.
[33]	YAN LT, WANG LL, YAO J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection[J]. Medicine (Baltimore), 2020, 99(8): e19248. DOI: 10.1097/MD.0000000000019248.
[34]	XU Q, GONG XH, GUO GQ. Diagnostic value of real - time shear wave elastography for early hepatic fibrosis in patients with chronic hepatitis B[J]. J Clin Exp Med, 2019, 18(20): 2225-2227. DOI: 10.3969/j.issn.1671-4695.2019.20.029. 许琴, 贡雪灏, 郭国强. 实时剪切波弹性成像对慢性乙型肝炎患者早期肝纤维化的诊断价值[J]. 临床和实验医学杂志, 2019, 18(20): 2225-2227. DOI: 10.3969/j.issn.1671-4695.2019.20.029.
[35]	TAO MM, ZHANG Y, HOU QB. Diagnostic value of transient elastography in the progression of cholestatic hepatic fibrosis[J]. Chin J Med Offic, 2019, 47(6): 565-566. DOI: 10.16680/j.1671-3826.2019.06.05. 陶苗苗, 张炎, 侯庆兵. 瞬时弹性成像技术肝硬度值测定在胆汁淤积性肝纤维化病变进展中诊断价值研究[J]. 临床军医杂志, 2019, 47(6): 565-566. DOI: 10.16680/j.1671-3826.2019.06.05.
[36]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[37]	XIE X, FENG Y, LYU Z, et al. Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101421. DOI: 10.1016/j.clinre.2020.03.021.
[38]	WU Z, DONG X, WANG G, et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J]. J Viral Hepat, 2019, 26(2): 287-296. DOI: 10.1111/jvh.13030.
[39]	AN HJ, GENG H, GE ZS, et al. Value of transient elastography combined with serological indexes in diagnosis of liver fibrosis and assessment of prognosis of patients with chronic hepatitis B[J]. Chin J Nosocomiol, 2020, 30(22): 3443-3447. DOI: 10.11816/cn.ni.2020-200197. 安红杰, 耿华, 葛志胜, 等. 瞬时弹性成像技术在慢性乙型肝炎肝纤维化诊断及预后评估中的价值[J]. 中华医院感染学杂志, 2020, 30(22): 3443-3447. DOI: 10.11816/cn.ni.2020-200197.
[40]	ZHAO CL, LI SY, ZHANG YJ. The value of Fibroscan combined with blood NLR and PDW in predicting the prognosis of liver cirrhosis caused by chronic HBV infection and its relationship with liver function[J]. Photogra Sci photochem, 2020, 38(4): 748-752. DOI: 10.7517/issn.1674.0475.200325. 赵丛林, 李树义, 张艳君. 瞬时弹性成像技术联合血NLR、PDW对慢性HBV感染相关肝硬化预后的预测价值及与肝功能的关联性研究[J]. 影像科学与光化学, 2020, 38(4): 748-752. DOI: 10.7517/issn.1674.0475.200325.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (677) PDF downloads(79)

Noninvasive diagnostic models for chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.10.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Noninvasive diagnostic models for chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.10.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content